Skip to main content
TipRanks
Go Ultimate75% OFF

N4 Pharma (THAT) AI Stock Analysis

7 Followers
GB:THAT

N4 Pharma

(LSE:THAT)

Select Model
Rating:37Underperform
Price Target:GBX 0.58â–²(1.57% Upside)
Action:downgraded
Date:09/08/26

The overall score is at the minimum of 37, driven by uniformly weak fundamentals and technicals. The company's financial position is fragile with significant cash burn and no clear path to profitability. This is compounded by a bearish technical picture with the stock trading below all major moving averages and deeply oversold conditions. The lack of positive valuation metrics or corporate catalysts offers no offsetting support.

Positive Factors
Proprietary Nuvec platformNuvec gives N4 Pharma a defined technology platform that can be applied across multiple drug-delivery markets, including vaccines and oncology. If development and external collaboration progress, the platform could support several commercialization paths rather than relying on one single therapeutic product.
Negative Factors
Persistent unprofitabilityDeep and recurring operating and net losses show that the current business is not economically self-sustaining. Margins substantially below zero indicate costs remain far above the revenue base, creating a durable execution challenge until products, partnerships or licensing generate materially larger income.

N4 Pharma (THAT) vs. iShares MSCI United Kingdom ETF (EWC)

-30%-20%-10%0%10%20%30%GB:THAT0.00%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 4.79M
Dividend Yield
―
Average Volume (3M)
904.38K
Price to Earnings (P/E)
-7.2
Beta (1Y)
1.32
Revenue Growth
2.12%
EPS Growth
29.17%
Country
UK
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

N4 Pharma Business Overview & Revenue Model

Company Description

Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular...

How the Company Makes Money

N4 Pharma is an R&D-stage drug delivery company; specific, consistently recurring commercial revenue streams are not publicly evidenced in the information available to me here, so a definitive breakdown of how it currently makes money cannot be state...

N4 Pharma Financial Statement Overview

Summary

Financial performance is very weak, typical of a pre-revenue biotech. Negligible revenue, persistent operating losses, negative cash flows, and a thin equity base relative to the cash burn rate result in a score at the bottom of the range.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue7,2167,2647,2821,95300
Gross Profit07,2647,2821,95300
EBITDA-1.39M-1.10M-1.22M-1.33M-1.19M-1.84M
Net Income-1.46M-1.21M-1.06M-1.27M-1.03M-1.54M
Balance Sheet
Total Assets2.71M1.17M775.77K1.28M2.17M2.34M
Cash, Cash Equivalents and Short-Term Investments1.50M1.08M625.97K1.03M1.92M1.78M
Total Debt000000
Total Liabilities245.66K97.96K124.37K81.73K77.89K212.73K
Stockholders Equity2.46M1.07M647.65K1.13M2.09M2.13M
Cash Flow
Free Cash Flow-1.46M-1.16M-971.50K-1.21M-828.26K-1.77M
Operating Cash Flow-1.46M-1.16M-971.50K-1.21M-828.26K-1.77M
Investing Cash Flow00078100
Financing Cash Flow1.24M1.61M570.36K315.90K963.77K677

N4 Pharma Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.57

Price Trends

50DMA0.59Negative
100DMA0.62Negative
200DMA0.59Negative

Market Momentum

MACD-0.01Negative
RSI44.88Neutral
STOCH78.63Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:THAT, the sentiment is Neutral. The current price of 0.57 is below the 20-day moving average (MA) of 0.58, below the 50-day MA of 0.59, and below the 200-day MA of 0.59, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 44.88 is Neutral, neither overbought nor oversold. The STOCH value of 78.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:THAT.

N4 Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:THAT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:EAHGB:EAH61NeutralGBP 56.24M25.702.55%―9.96%29.72%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:PXSGB:PXS44NeutralGBP 16.54M-70.50-44.68%―-2.14%0.00%
GB:STXGB:STX43NeutralGBP 32.76M-4.0864.57%―36.19%60.75%
GB:CHLLGB:CHLL38UnderperformGBP 836.68K-0.00233.76%―――
GB:THATGB:THAT37UnderperformGBP 14.18M-7.19-82.76%―2.12%29.17%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%GB:THATGB:EAHGB:CHLLGB:HELDGB:PXSGB:STXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:THAT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:THATN4 Pharma0.570.000.00%
GB:EAHEco Animal Health83.00-9.00-9.78%
GB:CHLLChill Brands Group PLC1.55-8.20-84.10%
GB:HELDMountfield Group plc0.90-0.05-5.26%
GB:PXSProvexis plc0.680.1118.26%
GB:STXShield Therapeutics3.05-4.65-60.39%

N4 Pharma Corporate Events

Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A TransactionsPrivate Placements and Financing

Thalia Therapeutics Accelerates RNA Strategy With Sanmirna Deal and Clinical-Stage Pipeline

Positive
Sep 30, 2026

Thalia Therapeutics reported interim results marking its strategic transformation from a delivery-platform business into a diversified, clinical-stage RNA therapeutics company in oncology and cardiovascular disease. The appointment of CEO Dr David So...

Business Operations and Strategy

Thalia Therapeutics Secures Chinese Patent for Lead AML Drug miRisten

Positive
Sep 29, 2026

Thalia Therapeutics has secured a new patent in China for its lead acute myeloid leukaemia drug candidate miRisten, extending protection for the RNA-based therapy in a major oncology market. The patent builds on existing rights licensed from City of...

Business Operations and StrategyProduct-Related Announcements

Thalia Therapeutics Advances Dual-Target RNA Cardiovascular Drug THAT-002

Positive
Sep 25, 2026

Thalia Therapeutics has completed initial chemistry synthesis for THAT-002, a bispecific siRNA gene-silencing therapy targeting PCSK9 and lipoprotein(a) to lower cardiovascular disease risk. The programme, developed with WuXi AppTec, marks a key earl...

Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A Transactions

Thalia Therapeutics Advances RNA Portfolio After Strategic Transformation

Positive
Sep 15, 2026

Thalia Therapeutics has completed its transition into a clinical-stage RNA therapeutics business after rebranding from N4 Pharma and acquiring Sanmirna Therapeutics, and will report interim results for the six months to 30 June 2026 on 30 September....

Business Operations and StrategyRegulatory Filings and Compliance

Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances

Positive
Jul 31, 2026

Thalia Therapeutics plc, an AIM-listed clinical-stage biotech specialising in RNA-based therapies for cancer and cardiovascular conditions, is advancing a differentiated pipeline anchored by validated genetic targets and proprietary delivery technolo...

Business Operations and StrategyExecutive/Board ChangesM&A TransactionsShareholder Meetings

Thalia Therapeutics Grants Major Director Option Package Tied to Share Price Targets

Neutral
Jul 23, 2026

Thalia Therapeutics has granted options over 200,000,000 ordinary shares to five directors under its share option plan, following its recent AGM and the completion of the acquisition of Sanmirna Therapeutics. The board says the ten-year options, pric...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 08, 2026